A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles (Pharmaceutical Research DOI: 10.1007/s11095-007-9318-0);A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles

Pharmaceutical Research

Volumn 24, Issue 10, 2007, Pages 1927-1935

  Gómez, Julia M Martínez ^a   Fischer, Stefan ^b   Csaba, Noèmi ^b   Kündig, Thomas M ^a   Merkle, Hans P ^b   Gander, Bruno ^b   Johansen, Pål ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

Adjuvants; Allergy; CpG; Immunotherapy; PLGA microspheres; Vaccine delivery

Indexed keywords

BEE VENOM; OLIGODEOXYNUCLEOTIDE; PHOSPHOLIPASE A2; POLYGLACTIN; PROTAMINE;

ALLERGY; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG FORMULATION; ENCAPSULATION; FEMALE; IMMUNOGENICITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 34548570058     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9386-1     Document Type: Erratum

References (41)

1. C. Alexander, A. B. Kay, and M. Larche. Peptide-based vaccines in the treatment of specific allergy. Curr. Drug Targets Inflamm. Allergy. 1:353-361 (2002).
2. F. Kussebi, F. Karamloo, C. Rhyner, P. Schmid-Grendelmeier, M. Salagianni, C. Mannhart, M. Akdis, L. Soldatova, Z. Markovic-Housley, B. R. Von Beust, T. Kundig, D. M. Kemeny, K. Blaser, R. Crameri, and C. A. Akdis. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J. Allergy Clin. Immunol. 115:323-329 (2005).
3. M. Larche. Anti-T-cell strategies in the treatment of allergic disease. Allergy 57 Suppl 72:20-23 (2002).
4. S. R. Durham, S. M. Walker, E. M. Varga, M. R. Jacobson, F. O'Brien, W. Noble, S. J. Till, Q. A. Hamid, and K. T. Nouri-Aria. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341:468-475 (1999).
5. A. W. Wheeler, and S. R. Woroniecki. Immunological adjuvants in allergy vaccines: Past, present and future. Allergol. Intern. 50:295-301 (2001).
6. S. Jilek, E. Walter, H. P. Merkle, and B. Corthesy. Modulation of allergic responses in mice by using biodegradable poly(lactide-co-glycolide) microspheres. J. Allergy Clin. Immunol. 114:943-950 (2004).
7. M. Peyre, R. Audran, F. Estevez, G. Corradin, B. Gander, D. Sesardic, and P. Johansen. Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. J. Control. Release 99:345-355 (2004).
8. M. Peyre, D. Sesardic, H. P. Merkle, B. Gander, and P. Johansen. An experimental divalent vaccine based on biodegradable microspheres induces protective immunity against tetanus and diphtheria. J. Pharm. Sci. 92:957-966 (2003).
9. S. Akira, and S. Sato. Toll-like receptors and their signaling mechanisms. Scand J. Infect. Dis. 35:555-562 (2003).
10. A. M. Krieg. CpG motives in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760 (2002).
11. A. M. Krieg, A.-K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546 (1995).
12. S. Freitas, A. Walz, H. P. Merkle, and B. Gander. Solvent extraction employing a static micromixer: a simple, robust and versatile technology for the microencapsulation of proteins. J. Microencapsul 20:67-85 (2003).
13. S. Gebrekidan, B. H. Woo, and P. P. DeLuca. Formulation and in vitro transfection efficiency of poly (D, L-lactide-co-glycolide) microspheres containing plasmid DNA for gene delivery. AAPS PharmSciTech 1:E28 (2000).
14. M. V. Nesterenko, M. Tilley, and S. J. Upton. A simple modification of Blum's silver stain method allows for 30 minute detection of proteins in polyacrylamide gels. J. Biochem. Biophys. Methods 28:239-242 (1994).
15. S. Fischer, C. Foerg, S. Ellenberger, H. P. Merkle, and B. Gander. One-step preparation of polyelectrolyte-coated PLGA microparticles and their functionalization with model ligands. J. Control. Release 111:135 (2006).
16. S. R. Durham, S. Ying, V. A. Varney, M. R. Jacobson, R. M. Sudderick, I. S. Mackay, A. B. Kay, and Q. A. Hamid. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J. Allergy Clin. Immunol. 97:1356-1365 (1996).
17. K. Gehlhar, M. Schlaak, W. Becker, and A. Bufe. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin. Exp. Allergy 29:497-506 (1999).
18. H. Secrist, C. J. Chelen, Y. Wen, J. D. Marshall, and D. T. Umetsu. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J. Exp. Med. 178:2123-2130 (1993).
19. K. T. Nouri-Aria, P. A. Wachholz, J. N. Francis, M. R. Jacobson, S. M. Walker, L. K. Wilcock, S. Q. Staple, R. C. Aalberse, S. J. Till, and S. R. Durham. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172:3252-3259 (2004).
20. S. J. Till, J. N. Francis, K. Nouri-Aria, and S. R. Durham. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 113:1025-1034; quiz 1035 (2004).
21. J. Bousquet, R. Lockey, and H. J. Malling. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102:558-562 (1998).
22. M. Ying, B. Gander, H. P. Merkle, and G. Corradin. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine 14:1442 (1996).
23. H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. A Toll-like receptor recognizes bacterial DNA. Nature 408:740 (2000).
24. B. Banerjee, K. J. Kelly, J. N. Fink, J. D. Henderson, Jr., N. K. Bansal, and V. P. Kurup. Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model of allergic aspergillosis. Infect. Immun. 72:6087-6094 (2004).
25. P. Johansen, G. Senti, J. M. Martinez Gomez, T. Storni, B. R. von Beust, B. Wuthrich, A. Bot, and T. M. Kundig. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin. Exp. Allergy 35:1591-8159 (2005).
26. P. S. Creticos, J. T. Schroeder, R. G. Hamilton, S. L. Balcer-Whaley, A. P. Khattignavong, R. Lindblad, H. Li, R. Coffman, V. Seyfert, J. J. Eiden, D. Broide, and the Immune Tolerance Network. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355:1445-1455 (2006).
27. S. K. Hunter, M. E. Andracki, and A. M. Krieg. Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. Am. J. Obstet. Gynecol. 185:1174 (2001).
28. S. Agrawal, J. Temsamani, W. Galbraith, and J. Tang. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28:7-16 (1995).
29. C. A. Farmanand, and D. J. Kornbrust. Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications. Toxicol. Pathol. 31 Suppl:119-122 (2003).
30. D. P. Sester, S. Naik, S. J. Beasley, D. A. Hume, and K. J. Stacey. Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J. Immunol. 165:4165-4173 (2000).
31. S. W. Lee, M. K. Song, K. H. Baek, Y. Park, J. K. Kim, C. H. Lee, H. K. Cheong, C. Cheong, and Y. C. Sung. Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. J. Immunol. 165:3631-3639 (2000).
32. Y. Park, Y. S. Chang, S. W. Lee, S. Y. Cho, Y. K. Kim, K. U. Min, Y. Y. Kim, S. H. Cho, and Y. C. Sung. The enhanced effect of a hexameric deoxyriboguanosine run conjugation to CpG oligodeoxynucleotides on protection against allergic asthma. J. Allergy Clin. Immunol. 108:570-576 (2001).
33. T. Storni, C. Ruedl, K. Schwarz, R. A. Schwendener, W. A. Renner, and M. F. Bachmann. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 172:1777-1785 (2004).
34. S. Liand, and L. Huang. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 4:891 (1997).
35. M. Gonzalez Ferreiro, R. M. Crooke, L. Tillman, G. Hardee, and R. Bodmeier. Stability of polycationic complexes of an antisense oligonucleotide in rat small intestine homogenates. Eur. J. Pharm. Biopharm. 55:19 (2003).
36. V. E. Schijns. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12:456-463 (2000).
37. C. Wild, M. Wallner, K. Hufnagl, H. Fuchs, K. Hoffmann-Sommergruber, H. Breiteneder, O. Scheiner, F. Ferreira, and U. Wiedermann. A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities. Allergy 62:33-41 (2007).
38. R. Crameri, S. Flückiger, I. Daigle, T. M. Kündig, and C. Rhyner. Design, engineering, and in-vitro evaluation of MHC class II targeting allergy vaccines. Allergy 62:197-206 (2007).
39. J. Bousquet, A. Hejjaoui, M. Soussana, and F. B. Michel. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J. Allergy Clin. Immunol. 85:490-497 (1990).
40. M. J. Kim, J. W. Lee, H. S. Yook, S. Y. Lee, M. C. Kim, and M. W. Byun. Changes in the antigenic and immunoglobulin E-binding properties of hen's egg albumin with the combination of heat and gamma irradiation treatment. J. Food Prot. 65:1192-1195 (2002).
41. P. Johansen, G. Senti, J. M. Martinez Gomez, B. Wuthrich, A. Bot, and T. M. Kundig. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur. J. Immunol. 35:3591-3598 (2005).